Note: You are reading this message either because your browser is not standards-compliant, or your browser failed to load our css files.

Newsletter
March 4, 2006
Volume VII, Issue 20
Home Page : www.otcjournal.com
Email Questions or Comments To: editor@otcjournal.com

To OTC Journal Members:
 

TelePlus (OTC BB: TLPE): January Sales Suggest Big '06

On Friday morning TLPE shared its January results with stock market investors. They were absolutely outstanding, and far better than the market understands.

The Liberty Wireless acquisition is looking like the perfect strategic move for the company. Here's some hard numbers to consider: TLPE delivered $2.2 million in sales in January, and delivered pre tax earnings of $130,000.

TLPE is coming off a $5 million Q4. $2.2 million in January suggests quarterly sales of $6.6 million. January is a slow month for the company, so one can easily assume $7 million is a fait accompli in Q1. These figures imply a 40% growth rate quarter over quarter. 40%, compounded quarterly, equates to a 384% annual growth rate (nearly four fold growth).

Here's the kicker and here's what the market doesn't understand: TLPE closed its unprofitable retail division as we turned to '06. The retail division accounted for $11 million of $19 million in sales in '05. Therefore, after closing out more than half of its revenue stream, the company is still able to deliver 40% quarter over quarter growth, and the highest revenue month in the company's history.

If they still owned the retail division, TLPE would have generate and astonishing $3.1 million in revenues in January alone. However, management did the right thing by shutting down its only unprofitable division, because positive cash flow is far more important than revenue.

This company is steamrollering its way through the small business and prepaid wireless telecom world. So long as they remain profitable, the risk of owning this stock is greatly diminished. So, what about the upside?

Take a look at the January surge in the stock. It was a great opportunity to take a trading profit, and I hope many of you did so when I suggested it at about the $.41 level.

TLPE is now setting up for another similar surge. With support in the $.28 to $.30 range, the starting point will be much higher than the previous $.25 blast off level.

Technicians call it a measured move. The next volcanic eruption in this stock should take it to roughly the $.46 level. If it's a streaky, spiking move, profit taking will be suggested once again. Each little surge into the $.35 range eats up overhead supply. Persistence breaks down resistance.

TLPE is a great penny stock to own because it currently is easy to accumulate. Accumulate in the $.29 to $.31 range, and wait for the next blast off. As long as the company keeps delivering fundamentally, it is coming sooner or later. Click Here to read Friday morning's press release.
 

Let Volume Be Your Guide

Are you a good enough trader to accumulate on pull backs, or do you jump in when a stock is rapidly rising on high volume? If you like to jump in as stocks rise, you are probably costing yourself a lot of money, and often end up with egg on your face as today's hot stock pulls back abruptly tomorrow. Big, spiky surges are selling opportunities, not buys.

TLPE is a great example- did you buy it when it was first covered by the OTC Journal at $.23, and sell it at $.41 when everyone else was buying? Or, did you buy it because it was rolling through the mid $.30's range and you thought it would trade up forever. If you jumped in at the latter, you need to improve your trading strategies.

If you are looking to accumulate a favorite stock on pullbacks, how do you know if a correction is strictly technical, or a signal of problems under the surface? Let volume be your guide. Here are two recent examples in OTC Journal ideas which you may find enlightening.

First: Let's look at a stock that has been trading poorly of late. HDY has been selling off since their annual shareholders meeting nine trading days ago. I did not attend, but have spoken with a couple of shareholders that did attend and were very disappointed with management's excuses concerning delays in getting the drilling permits in Guinea. The stock sold off fairly violently that day. The actual day of the meeting is shown by the arrows in the chart. Note the big drop in the stock is associated with a very high volume day. 

I have since sold my entire position in this stock, betting it will continue working its way lower. If they pull a rabbit out of the hat and deliver the drilling permits, the stock will turn around and make me look silly. However, reading between the lines, I don't believe it is imminent. I'll be looking to re enter this stock in the $1.60 to $1.75 range if it gets there. I still believe they will get the permits eventually.

Dexcom's temporary swoon this past week represents the opposite kind of opportunity. On Tuesday, DXCM released year end '05 numbers. Q4 losses were a little steeper than the market expected, and the stock starting selling of early in the day. The stock had closed at $17 the night before, and reopened for trading the next day at the same level. 

Within a half an hour of the open, the stock started down. However, there was very minimal volume associated with the correction. To me, this suggested the serious money couldn't care less about Q4, and had no intention of selling. Owning this stock is all about getting the FDA Approval.

I quickly checked the chart for the 61.8% retracement level, and determined it was $16.30. I filed a limit order to buy 1,000 shares at that level. It took about 2 hours, but when I was filled the stock had only traded about 30,000 shares. Minimum volume for a $.70 pullback. After being filled I picked up another 1,000 shares.

Apparently, I am not the only trader looking to buy at perfect 61.8% retracement in this stock. The low trade of the day was $16.28, and the stock turned right around and actually closed higher than where it opened that day. Friday's closing price was $18.20- nearly a full 2 point gain in three trading days.

Here's the point of the story. Both stocks suffered corrections. In my view, one was a buying opportunity, and the other was a sell. I let volume be my guide- the low volume pullback was the buy, the high volume pullback was the sell. When you are trying to determine if a correction is a buying opportunity or a leading indicator of a problem, let the volume help you decide.
 

Comments in the BLOG

There were a couple of new BLOG entries on Thursday afternoon. The first BLOG concerns HDY- I believe the stock will continue grinding down slowly for some time and I sold the rest of my shares. Check the BLOG for comments. Also- BrandPartners (BPTR) has perked up a bit on very positive mid week news. Check the BLOG for full coverage and comments on the event. 

To use the BLOG, simply go to the home page at www.otcjournal.com - the BLOG will scroll down automatically on the right side of your screen. You can look there by company. The most current journal entries appear in the middle of your screen in chronological order. Check back frequently for updates particularly when stocks are moving to overbought or oversold levels or in volatile markets. Your questions and postings do not automatically appear, so don't bother posting the same question multiple times. I personally go through to moderate and respond to every reasonable question.
 

Subscribe

Information is power and timely information is profitable. Become informed and profit from OTC Journal Profiles and Trading Alerts by becoming a Preferred Member today. There is no cost associated with your email subscription. Add your email address below and make sure to check your email inbox and confirm your opt-in request to start receiving the OTC Journal Email Newsletter on a regular basis.

To ensure newsletter delivery, you can add any additional email addresses you may have to the OTC Journal Member List. Receiving the OTC Journal Newsletter in multiple locations is the best way of making sure you don't miss the next investing or trading opportunity! For web based email addresses, the OTC Journal recommends @yahoo.com or @aol.com for timely and reliable email newsletter delivery.

Subscribe Here

Note: Your email address will be kept strictly confidential, and will not be shared with any other entity for any purpose at any time. If you no longer wish to receive the OTC Journal, simply follow the instructions located at the bottom of every OTC Journal Newsletter Edition.

Disclaimer
The OTCjournal.com Newsletter is an independent electronic publication committed to providing our readers with factual information on selected  publicly traded companies. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward  maximizing the upside potential for investors while minimizing the downside risk, whenever possible.  Moreover, as detailed below, this publication accepts compensation from certain of the companies which it features.  Likewise, this newsletter is owned by MarketByte, LLC.  To the degrees enumerated herein,  this newsletter should not be regarded as an independent publication.

Go Here to view our compensation on every company we have ever covered, or visit the following web address:  http://www.otcjournal.com/disclaimer.html for our full profiles and http://www.otcjournal.com/trading-alerts/disclaimer.html for Trading Alerts. MarketByte LLC has been paid a fee of $25,000 and 600,000 newly issued restricted shares by Teleplus Inc for coverage of the company.

All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities  mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.

From time to time MarketByte LLC sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.

The editor, members of the editor's family, and/or entities with which they are affiliated aside from MarketBtye LLC itself, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter. Some of the companies featured in the OTC Journal pay a cash ESP fee to an affiliated technology company ranging from $2,000 to $5,000 per month for internet related technology services.

The Trustee of the MarketByte LLC Defined Benefit and Trust (“the MarketByte Pension Plan”) has invested approximately $140,0000 in Dutchess Private Equities II LP (“the Dutchess Limited Partnership”), a limited partnership in which the MarketByte Pension Plan is a limited partner.  No one associated with the MarketByte Pension Plan has any knowledge, information, or control as to any past, present, or future investment activities of the Dutchess Limited Partnership.  The Dutchess Limited Partnership is one of two hedge funds managed by Dutchess Advisors.  Dutchess Advisors periodically refers companies to MarketByte LLC for possible coverage by one of the MarketByte LLC publications, which publications include The OTCJournal.com Newsletter.  Dutchess Advisors may or may not own shares in the companies that it so refers to MarketByte.  MarketByte has no information (outside of information readily accessible to the general public such as SEC filings) as to whether Dutchess Advisors owns any shares in the companies that it refers to MarketByte LLC.  The above relationships should be viewed as a potential and/or actual conflict of interest by shareholders and prospective shareholders of MarketByte LLC client companies.

The profiles, critiques, and other editorial content of the OTCjournal.com may contain statements that appear foward relating to the expected capabilities of the companies mentioned herein.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN  SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN  CONSENT OF THE EDITORS OF OTCjournal.com.

We encourage our readers to invest carefully and read the investor information available at the web sites of  the Securities and Exchange Commission ("SEC") at http://www.sec.govand/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at  http://www.sec.gov/consumer/cyberfr.htm. Disclaimer ID:$subst('Recip.userid') Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.  MarketByte LLC's mailing address is 3525 Del Mar Heights Rd #334, San Diego, CA 92130.


Unsubscribe Here

You can unsubscribe from this list at any time by Clicking Here. If you are having difficulty removing yourself or wish to change your address please go to http://www.otcjournal.com/opt.html?.

 

Click Here to View the OTC Journal Disclosure

China Energy Recovery, Inc.
Newsletter
Editions
RSS Subscribe

To subscribe to our newsletter, please enter your email address below.

7 Minutes To Wealth
May 12, 2012

Share
Market Summary
Nasdaq 2857.51 +10.30 (+0.36%)
Russell 2K 766.65 +2.01 (+0.26%)
S&P 500 1323.98 +7.99 (+0.61%)
S&P 100 603.99 +4.15 (+0.69%)
Quotes are delayed 20 minutes.

Add to Google

China Stocks and Penny Stocks - Discover Tomorrow's Winners Today

© 2012 OTC Journal